IMMUCELL CORP /DE/ — Investor Relations & Filings
ImmuCell Corporation is an animal health company that develops, manufactures, and markets scientifically-proven products to improve the health and productivity of dairy and beef cattle. The company focuses on disease prevention as a means to reduce the use of antibiotics. Its flagship product line, First Defense®, is a USDA-accredited, colostrum-derived product providing newborn calves with immediate immunity against the primary viral and bacterial causes of scours. ImmuCell is also developing Re-Tain®, a purified nisin-based intramammary treatment for subclinical mastitis in dairy cows, which is pending regulatory approval. The company's core competency lies in its ability to concentrate, purify, and quantify specific colostrum antibodies on a commercial scale to create cost-effective health solutions for producers.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| FORM 8-K | 2026-05-14 | English | |
| FORM 10-K/A | 2026-05-13 | English | |
| FORM 8-K | 2026-05-08 | English | |
| DEF 14A - IMMUCELL CORP /DE/ (0000811641) (Filer) | 2026-04-24 | English | |
| FORM PRE 14A | 2026-04-14 | English | |
| FORM 8-K | 2026-04-14 | English |
Browse filings by year
32 years- 2026 18 filings
- 2025 32 filings
- 2024 40 filings
- 2023 32 filings
- 2022 34 filings
- 2021 28 filings
- 2020 29 filings
- 2019 26 filings
- 2018 35 filings
- 2017 36 filings
- 2016 53 filings
- 2015 26 filings
- 2014 30 filings
- 2013 23 filings
- 2012 16 filings
- 2011 30 filings
- 2010 25 filings
- 2009 31 filings
- 2008 29 filings
- 2007 34 filings
- 2006 19 filings
- 2005 28 filings
- 2004 20 filings
- 2003 27 filings
- 2002 15 filings
- 2001 19 filings
- 2000 7 filings
- 1999 6 filings
- 1998 9 filings
- 1997 6 filings
- 1996 6 filings
- 1995 5 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46257425 | FORM 8-K | 2026-05-14 | English | ||
| 46108336 | FORM 10-K/A | 2026-05-13 | English | ||
| 46108346 | FORM 8-K | 2026-05-08 | English | ||
| 36127480 | DEF 14A - IMMUCELL CORP /DE/ (0000811641) (Filer) | 2026-04-24 | English | ||
| 46108352 | FORM PRE 14A | 2026-04-14 | English | ||
| 46108383 | FORM 8-K | 2026-04-14 | English | ||
| 46108392 | FORM 8-K | 2026-04-08 | English | ||
| 46108443 | FORM 10-K | 2026-03-30 | English | ||
| 33036047 | 4 - IMMUCELL CORP /DE/ (0000811641) (Issuer) | 2026-03-25 | English | ||
| 33013976 | 4/A - IMMUCELL CORP /DE/ (0000811641) (Issuer) | 2026-03-23 | English | ||
| 46108452 | FORM 8-K | 2026-03-18 | English | ||
| 46108456 | FORM 8-K | 2026-03-04 | English | ||
| 18815618 | 8-K Filing | 2026-02-09 | English | ||
| 18815622 | 8-K Filing | 2026-02-02 | English | ||
| 18815623 | 4 Filing | 2026-01-29 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
IMMUCELL CORP /DE/ via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34519/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34519 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34519 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34519 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34519}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for IMMUCELL CORP /DE/ (id: 34519)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.